Johnson & Johnson (JNJ) Stock Forecast & Price Target

Johnson & Johnson
Bull Case

Here are some ways that investors could benefit from investing in Johnson & Johnson:

• Johnson & Johnson recently demonstrated significant clinical progress in its oncology franchise, with new Phase 3 modeling for the TECVAYLI plus DARZALEX FASPRO combination indicating that approximately 87% of early-line relapsed/refractory multiple myeloma patients could face mortality risk comparable to the general population, supporting long-term growth potential.
• The company's neuroscience portfolio is expanding as CAPLYTA delivered statistically significant and rapid symptom improvement in a Phase 3 study of bipolar I mania, which could support broader revenue growth if approved for this additional indication alongside bipolar depression and schizophrenia.
• Johnson & Johnson is strengthening its immunology pipeline with the FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis, providing a potential successor to declining STELARA sales and expanding its market reach in this therapeutic area.
• Investors can benefit from the company's consistent dividend payments, as Johnson & Johnson recently paid a quarterly dividend of $1.34 per share, representing an annualized yield of approximately 2.0% and a payout ratio of 62.11%, which offers a steady income stream.
• With the current stock price at $270.94, Johnson & Johnson offers a defensive investment profile characterized by a low beta of 0.24, suggesting lower volatility compared to the broader market, which may appeal to risk-averse investors seeking stability.